Bio

Sunny joined Aisling in 2019 and serves as a Principal. Prior to Aisling, Sunny was an Associate at Leerink Partners, a healthcare-specialist investment bank, focusing on biopharma/therapeutics. Prior to Leerink Partners, Sunny was a Quantitative Analyst at Bank of America Merrill Lynch specializing in credit derivative products. He was also a research associate working in oncology drug development prior to his careers in finance and investing. Sunny currently serves as a board observer for Garuda Therapeutics, Mindful Health Solutions, and Wugen. His prior board service includes Forge Biologics (acquired by Ajinomoto Pharma) and Monte Rosa Therapeutics (observer). Sunny obtained an M.B.A. from Columbia Business School and a B.S. in Biomedical Engineering from Georgia Tech where he received high honors and was a HOPE & Zell Miller Scholar recipient.